Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • Archive
    • Minireviews
    • JVI Classic Spotlights
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JVI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Journal of Virology
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • Archive
    • Minireviews
    • JVI Classic Spotlights
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JVI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Virus-Cell Interactions

Varicella-Zoster Virus Immediate-Early 63 Protein Interacts with Human Antisilencing Function 1 Protein and Alters Its Ability To Bind Histones H3.1 and H3.3

Aruna P. Ambagala, Trent Bosma, Mir A. Ali, Maxim Poustovoitov, Jason J. Chen, Michael D. Gershon, Peter D. Adams, Jeffrey I. Cohen
Aruna P. Ambagala
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Trent Bosma
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mir A. Ali
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maxim Poustovoitov
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jason J. Chen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael D. Gershon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter D. Adams
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeffrey I. Cohen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/JVI.00645-08
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • FIG. 1.
    • Open in new tab
    • Download powerpoint
    FIG. 1.

    Interaction of VZV IE63 with human antisilencing function 1 protein (ASF1) in VZV-infected cells. Human melanoma (MeWo) cells uninfected or infected with VZV ROka were lysed at 48 h postinfection, and equal amounts of lysates were incubated with mouse anti-VZV IE63 (9A12) (A and D), mouse anti-ASF1a (MPH7, IgG1) (C and D), or mouse anti-myc 9E10 (IgG1) (B and C) antibodies. Immune complexes were precipitated and immunoblotted with rabbit anti-ASF1 antibody which detects human ASF1a and ASF1b (A and C); rabbit anti-VZV IE63 antibody (C and D); rabbit antibody to IE62, ORF4 protein, or ORF61 protein; or mouse monoclonal antibody to gE (D). IP, immunoprecipitation. (B) Characterization of anti-ASF1a mouse monoclonal antibodies MPH7 and MPB1. U2OS cell lysates were immunoprecipitated with mouse monoclonal antibodies to ASF1a (MPH7 and MPB1), rabbit polyclonal antibody to ASF1a (antibody 87), or control antibodies (rabbit anti-mouse polyclonal antibody [RAM] or mouse anti-myc monoclonal antibody [9E10]). Immunoprecipitates were resolved by SDS-polyacrylamide gel electrophoresis and then immunoblotted with a cocktail of purified rabbit polyclonal antibodies to ASF1a and ASF1b (antibodies 87 and 88). The left lane shows whole-cell extract of U2OS cells.

  • FIG. 2.
    • Open in new tab
    • Download powerpoint
    FIG. 2.

    Interaction of VZV IE63 with human ASF1a and ASF1b. (A) MeWo cells were transiently transfected with plasmids expressing myc-tagged human ASF1a (p408) or human ASF1b (p542). At 24 h posttransfection, the cells were infected with VZV ROka-T7, and 48 h postinfection, the cells were lysed and the clarified lysates were incubated with mouse anti-myc antibody (Ab). The immune complexes were precipitated and immunoblotted with rabbit anti-ASF1 or rabbit anti-VZV IE63 antibodies. IP, immunoprecipitation. (B) ASF1a, ASF1b, and chimeric ASF1 constructs used to identify the region of ASF1a important for binding to VZV IE63. (C) COS cells were transiently transfected with plasmids expressing myc-tagged, full-length ASF1a (p408), ASF1b (p542), and ASF1a and ASF1b (p601, p941, p942, p1051, or p1052) chimeras or pmaxGFP together with a plasmid expressing full-length VZV IE63 (pCI63). At 48 h posttransfection, the cells were lysed and equal amounts of clarified lysates were immunoblotted with mouse anti-myc monoclonal antibody (9E10), mouse anti-beta-actin antibody (clone AC-15; Sigma-Aldrich), or rabbit anti-VZV IE63 antibodies. (D) Equal amounts of lysates (comparable to those used in panel B) were incubated with mouse anti-myc antibody, and immune complexes were precipitated and immunoblotted with rabbit anti-VZV IE63 antibody or mouse anti-myc antibody. The numbers below the IE63 panel indicate the intensities of the IE63 bands relative to those in cells transfected with ASF1a (p408), normalized to the intensities of the corresponding ASF1 bands on the basis of densitometry by using ImageJ software (http://rsb.info.nih.gov/ij/). The IE63 doublets in Fig. 2D were seen when plasmids expressing IE63 were transfected into COS cells (also seen in Fig. 3C) but not into HeLa cells (Fig. 5C) and are likely due to differences in cell type used.

  • FIG. 3.
    • Open in new tab
    • Download powerpoint
    FIG. 3.

    Amino acids 170 to 280 and putative phosphorylation sites of VZV IE63 are important for the interaction with ASF1. (A) Equal numbers of MeWo cells that were uninfected or infected with VZV ROka, ROka63-KpnI, or ROka63-AccI were lysed at 48 h postinfection, and equal amounts were immunoblotted with rabbit anti-VZV IE63 antibody. Another aliquot of each lysate was incubated with mouse anti-ASF1a monoclonal antibody MPH7, and the immunoprecipitates were immunoblotted with rabbit anti-VZV IE63 antibody. The faint bands in the ROka (lane 6) and ROka63-AccI (lane 8) cells at 26 kDa are due to the light chain of the MPH7 antibody. IP, immunoprecipitation. (B) ASF1 interacts very weakly with IE63-5M in ROka63-5M-infected MeWo cells. MeWo cells infected with VZV ROka or ROka63-5M were lysed at 48 h postinfection. An aliquot of each lysate was incubated with mouse anti-VZV IE63 (9A12) monoclonal antibody, and immune complexes were recovered on protein G-Sepharose beads and eluted. A portion of cell lysate (input), eluted immune complexes, and a portion of supernatant remaining after immunoprecipitation (unbound lysate) were subjected to immunoblotting using rabbit anti-VZV IE63 antibody and rabbit anti-ASF1 antibody. (C) COS cells were transiently transfected with a plasmid expressing myc-tagged, full-length ASF1a (p408) and plasmid pCI63, pmaxGFP, pcDNA63-5M, or pcDNA63-10M. At 48 h posttransfection, the cells were lysed and equal amounts of clarified lysates were immunoblotted with mouse anti-myc antibody (to detect ASF1a) and rabbit anti-VZV 63 antibody. Another aliquot of each lysate was incubated with mouse anti-myc antibody, and the immune complexes were immunoblotted with rabbit anti-VZV IE63 or mouse anti-myc antibodies. (D) Map showing ASF1 binding site and other domains of VZV IE63. “NLS” are nuclear localization signals, and “phosphorylation” is the region which contains phosphorylation sites mutated in ROka63-5M.

  • FIG. 4.
    • Open in new tab
    • Download powerpoint
    FIG. 4.

    Subcellular localization of ASF1 and VZV IE63. (A and B) HeLa cells were cotransfected with plasmid p408 expressing myc-tagged ASF1a and either plasmid pCI-HA63 expressing HA-tagged, full-length VZV IE63 (A) or pCI-HA63KpnI, which expresses the HA-tagged amino-terminal 208 amino acids of VZV IE63 (B). At 48 h posttransfection, the cells were fixed, permeabilized, and stained with mouse anti-myc monoclonal antibody and rat anti-HA monoclonal antibody, followed by Alexa Fluor 488 (green)-conjugated goat anti-rat IgG antibody, Alexa Fluor 594 (red)-conjugated goat anti-mouse IgG1 antibody, and DAPI. The arrows in panels A and B indicate cells expressing only ASF1a or IE63. (C) Cultured guinea pig enteric neurons were uninfected (top row) or infected with either cell-free (middle row) or cell-associated (bottom row) VZV, and at 3 days postinfection, the neurons were fixed, permeabilized, and stained with mouse anti-IE63 monoclonal antibody 9D12, rabbit anti-ASF1a antibody, and guinea pig anti-neuron specific ubiquitin carboxyl-terminal hydrolase L1 antibody, followed by goat anti-rabbit Alexa Fluor 488 (green), goat anti-mouse Alexa Fluor 594 (red), and biotin labeled anti-guinea pig antibody, with avidin-conjugated Alexa 680 (purple) and bisbenzimide used to stain DNA (blue).

  • FIG. 5.
    • Open in new tab
    • Download powerpoint
    FIG. 5.

    Effect of VZV IE63 on the interaction of ASF1 with histones H3.1 and H3.3. (A) HeLa S 3.1 and HeLa S 3.3 cells, which express C-terminal HA-tagged H3.1 and H3.3, respectively, were nucleofected with plasmid pmaxGFP or pCI63, lysed, and immunoblotted with rabbit anti-ASF1 antibody or mouse anti-HA antibody (to detect H3.1 and H3.3). Another aliquot of each lysate was incubated with mouse anti-HA antibody, and the immune complexes were precipitated and immunoblotted with rabbit anti-ASF1 antibody or mouse anti-HA antibody. IP, immunoprecipitation. (B) HeLa S 3.1 cells were nucleofected with plasmid pCI, pCI63, pmaxGFP, or pCMV62; lysed; and immunoblotted with rabbit anti-ASF1 or mouse anti-HA antibody. Another aliquot of each lysate was incubated with mouse anti-HA antibody, and the immune complexes were precipitated and immunoblotted with rabbit anti-ASF1 antibody or mouse anti-HA antibody. (C) HeLa S 3.1 cells were nucleofected with plasmid pmaxGFP, pCI63, pcDNA63-5M, or pcDNA63-10M; lysed; and immunoblotted with rabbit anti-VZV IE63 or mouse anti-HA antibody. Another aliquot of each lysate was incubated with mouse anti-HA antibody, and the immune complexes were precipitated and immunoblotted with rabbit anti-ASF1 antibody or mouse anti-HA antibody. The intensities of the ASF1 bands were quantified using ImageJ software (http://rsb.info.nih.gov/ij/) and normalized to the intensities of the corresponding IE63 bands in the input lysate, and this ratio is shown below the ASF1 bands.

PreviousNext
Back to top
Download PDF
Citation Tools
Varicella-Zoster Virus Immediate-Early 63 Protein Interacts with Human Antisilencing Function 1 Protein and Alters Its Ability To Bind Histones H3.1 and H3.3
Aruna P. Ambagala, Trent Bosma, Mir A. Ali, Maxim Poustovoitov, Jason J. Chen, Michael D. Gershon, Peter D. Adams, Jeffrey I. Cohen
Journal of Virology Dec 2008, 83 (1) 200-209; DOI: 10.1128/JVI.00645-08

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Journal of Virology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Varicella-Zoster Virus Immediate-Early 63 Protein Interacts with Human Antisilencing Function 1 Protein and Alters Its Ability To Bind Histones H3.1 and H3.3
(Your Name) has forwarded a page to you from Journal of Virology
(Your Name) thought you would be interested in this article in Journal of Virology.
Share
Varicella-Zoster Virus Immediate-Early 63 Protein Interacts with Human Antisilencing Function 1 Protein and Alters Its Ability To Bind Histones H3.1 and H3.3
Aruna P. Ambagala, Trent Bosma, Mir A. Ali, Maxim Poustovoitov, Jason J. Chen, Michael D. Gershon, Peter D. Adams, Jeffrey I. Cohen
Journal of Virology Dec 2008, 83 (1) 200-209; DOI: 10.1128/JVI.00645-08
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

About

  • About JVI
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #Jvirology

@ASMicrobiology

       

 

JVI in collaboration with

American Society for Virology

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

Copyright © 2019 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0022-538X; Online ISSN: 1098-5514